欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (10): 1112-1116.

• 基础研究 • 上一篇    下一篇

依折麦布与考来替泊交替给药对于高脂血症大鼠脂代谢的调节作用

杨 毅,官俏兵,郭 丽,李文燕,张 慧,韩晨阳   

  1. 嘉兴市第二医院,嘉兴 314001,浙江
  • 收稿日期:2017-04-05 修回日期:2017-05-17 出版日期:2017-10-26 发布日期:2017-11-13
  • 通讯作者: 韩晨阳,男,硕士,药师,研究方向:药理学。 Tel:13736496736E-mail:691513770@qq.com
  • 作者简介:杨毅,男,本科,副主任药师,研究方向:药理学。 Tel:13967351048 E-mail:wasd92@126.com
  • 基金资助:

    浙江省科技厅项目(2017C37174)

Alternate dosing of ezetimibe and colestipol on regulating lipid metabolism in hyperlipidemia rats

YANG Yi, GUAN Qiaobing, GUO Li, LI Wenyan, ZHANG Hui, HAN Chenyang   

  1. The Second Hospital of Jiaxing, Jiaxing314001, Zhejiang, China
  • Received:2017-04-05 Revised:2017-05-17 Online:2017-10-26 Published:2017-11-13

摘要:

目的: 探讨依折麦布和考来替泊交替给药对于高脂血症大鼠的脂代谢调节作用。方法: 选用清洁级的SD大鼠50只,雌雄各半,通过高脂饲料饲养造模,造模成功后随机分组,设置正常组、模型组、实验组(依折麦布组、考来替泊组、依折麦布+考来替泊组),实验组每日灌胃给药,正常组和模型组给予生理盐水,连续给药8周,检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)含量以及乙酰辅酶A羧化酶(ACC)、脂肪酸合酶(FAS)、3-羟基-3-甲基戊酰辅酶A还原酶( HMGR)、肝脏肉毒碱棕榈酰转移酶 I(CPT-I)的mRNA的表达。结果: 实验组大鼠血清TC、TG、HDL-C、LDL-C含量以及ACC、FAS、HMGR、CPT-I的mRNA表达相比模型组均有降低且交替用药组较单一用药组含量显著降低(P<0.05)。结论: 依折麦布和考来替泊交替给药对于高脂血症大鼠脂代谢的调节优于单一用药,但是对人体的作用还需要临床验证。

关键词: 依折麦布, 考来替泊, 高脂血症

Abstract:

AIM: To explore alternate dosing of ezetimibe and colestipol on regulating for lipid metabolism in hyperlipidemia rats.  METHODS:Fifty rats of clean grade, half male and female were modeling through feeding high fat diet; the rats were randomly divided into normal group, model group, and experimental groups (including ezetimibe group, colestipol group, ezetimibe+colestipol group); experimental groups received gavage administration, while the normal group and model group were given normal saline for 8 weeks; TG, TC, HDL-C, LDL-C and ACC, FAS, HMGR, CPT-I expression of mRNA in serum were thereafter detected. RESULTS: The levels of TC, TG, LDL-C and AAC, FAS, HMGR mRNA in serum were decreased, and levels of ezetimibe+colestipol group were significantly lower than those of single drug group (P<0.05). CONCLUSION: Alternate dosing of ezetimibe and colestipol was better than single medication in regulating lipid metabolism in hyperlipidemia rats, but the effect on human body still needs further clinical validation.

Key words: ezetimibe, colestipol, hyperlipidemia

中图分类号: